Cellebrite DI Ltd.
NASDAQ:CLBTSoftware - Infrastructure
-$0.05 today
- Market cap
- $2.68B
- Beta
- 1.17
- P/E (TTM)
- 42.6
- EPS (TTM)
- $0.29
Volume 3.48M
Average 2.08M
CLBT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cellebrite DI Ltd.NASDAQ: CLBT
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA grows, but more slowly than its trailing trend
Q3 FY2026 EBITDA of $36.21M rose 34.2% year over year, behind the +152.3% change in trailing-twelve-month EBITDA. Sequentially, it rose 118.9% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- EBITDA amounted to 21.7% of revenue in FY2025, down 44.5 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $206.92M (+100.8%) for the fiscal year ending Dec 2026, a slowdown from the +138.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $36.21M+118.9% QoQ
- Last fiscal yearDec 2025
- $103.07M+138.8% YoY
- LTMSep 2026
- $122.86M+152.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +34.2% | -20.4% | -54.5 pp |
| 1 year | +138.8% | +100.8% | -38.1 pp |
| 3-year CAGR | -7.5% | +34.7% | +42.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 103.07M USD
- Year-over-year change
- +138.8%
- 4-year CAGR
- +3.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.07M | +138.8% |
| FY2024 | 2024-12-31 | (265.35M) | -305.7% |
| FY2023 | 2023-12-31 | (65.41M) | -150.3% |
| FY2022 | 2022-12-31 | 130.1M | +45.4% |
| FY2021 | 2021-12-31 | 89.47M | — |
EBITDA vs competitors
How CLBT compares with its peers on the latest reported figures
- CLBT's LTM Sep 2026 EBITDA of $122.86M is the 2nd highest of the 4 companies compared; the peer median is $3.16M.
- Its year-over-year change of +152.3% is the highest of 4, against a peer median of -65.6%.
- EBITDA amounts to 22.9% of revenue for CLBT, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $564.69M | +81.6% | -3.8% | 16.5% | |
| LTM Sep 2026 | $122.86M | +152.3% | -7.5% | 22.9% | |
| LTM Mar 2026 | $3.16M | -65.6% | — | 11.1% | |
| LTM Mar 2026 | -$5.02M | -249.3% | -58.4% | 5.0% | |
| Peer median (excluding CLBT) | $3.16M | -65.6% | -31.1% | 11.1% | |
Competitors are the stored peer set for CLBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 246.25M | 270.65M | 325.11M | 401.2M | 475.68M |
| Cost of Revenue | 42.56M | 50.75M | 53.23M | 62.59M | 75.17M |
| Gross Profit | 203.69M | 219.91M | 271.88M | 338.61M | 400.5M |
| Gross Margin | 82.7% | 81.3% | 83.6% | 84.4% | 84.2% |
| Research & Development | 65.54M | 80.62M | 84.39M | 98.42M | 113.88M |
| Selling, General & Admin | 124.33M | 138.24M | 154.26M | 183.29M | 220.15M |
| Operating Expenses | 189.87M | 218.86M | 238.64M | 281.7M | 334.02M |
| Depreciation & Amortization | 7.01M | 9.19M | 10.01M | 10.61M | 11.87M |
| EBITDA | 89.47M | 130.1M | (65.41M) | (265.35M) | 103.07M |
| EBITDA Margin | 36.3% | 48.1% | -20.1% | -66.1% | 21.7% |
| Operating Income | 13.82M | 1.04M | 33.24M | 56.91M | 66.48M |
| Operating Margin | 5.6% | 0.4% | 10.2% | 14.2% | 14.0% |
| Interest Income | 847K | 2.03M | 8.89M | 18.22M | 24.2M |
| Interest Expense | 153K | 149K | 0 | 349.76M | 0 |
| Other Income / Expenses | 68.48M | 119.72M | (108.8M) | (332.89M) | 24.2M |
| Income Before Tax | 82.31M | 120.76M | (75.56M) | (275.98M) | 90.68M |
| Pre-Tax Margin | 33.4% | 44.6% | -23.2% | -68.8% | 19.1% |
| Income Tax Expense | 10.91M | (45K) | 5.54M | 7.02M | 12.35M |
| Net Income | 71.4M | 120.81M | (81.1M) | (283.01M) | 78.33M |
| Net Margin | 29.0% | 44.6% | -24.9% | -70.5% | 16.5% |
| EPS (Basic) | 0.50 | 0.64 | (0.43) | (1.35) | 0.31 |
| EPS (Diluted) | 0.44 | 0.59 | (0.43) | (1.35) | 0.31 |
| Weighted Avg Shares | 144M | 182.69M | 190.15M | 209.47M | 249.9M |
| Weighted Avg Shares (Diluted) | 161.54M | 195.39M | 190.15M | 209.47M | 249.9M |
Cellebrite DI Ltd.
NASDAQ:CLBT
Intrinsic Alpha fair value
Locked
Current Price
$10.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.